EUVIMEDEUVIMED entdecken
Vergleichsstudie

A disproportionality analysis of antipsychotic-induced hyperprolactinemia based on FDA adverse event reporting system

Min Song, Dong Li, Jing Peng, Na Wang, Mei Zhang, Xiao-Lei Ren

Int. Journal of Clinical Pharmacology and Therapeutics · 2024

DOI: 10.5414/cp204518 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Int. Journal of Clinical Pharmacology and Therapeutics, 2024. Verfasst von Min Song und 5 weiteren Autor:innen. Hauptthemen laut MEDLINE: Hyperprolactinemia, Antipsychotic Agents, Adverse Drug Reaction Reporting Systems, United States Food and Drug Administration. Die Arbeit wurde bisher 4-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HyperprolactinemiaAntipsychotic AgentsAdverse Drug Reaction Reporting SystemsUnited States Food and Drug AdministrationHumansFemaleMaleUnited StatesAdultMiddle AgedAdolescentYoung AdultAgedSex FactorsRisk FactorsAge FactorsChildTime Factors

Substanzen

Antipsychotic Agents

Zitieren

APA

Song, M., Li, D., Peng, J., Wang, N., Zhang, M., & Ren, X. L. (2024). A disproportionality analysis of antipsychotic-induced hyperprolactinemia based on FDA adverse event reporting system. Int. Journal of Clinical Pharmacology and Therapeutics. https://doi.org/10.5414/cp204518

Vancouver

Song M, Li D, Peng J, Wang N, Zhang M, Ren XL. A disproportionality analysis of antipsychotic-induced hyperprolactinemia based on FDA adverse event reporting system. Int. Journal of Clinical Pharmacology and Therapeutics. 2024. doi:10.5414/cp204518

BibTeX
@article{Song2024,
  author = {Song, Min and Li, Dong and Peng, Jing and Wang, Na and Zhang, Mei and Ren, Xiao-Lei},
  title = {A disproportionality analysis of antipsychotic-induced hyperprolactinemia based on FDA adverse event reporting system},
  journal = {Int. Journal of Clinical Pharmacology and Therapeutics},
  year = {2024},
  doi = {10.5414/cp204518}
}
Kostenlos starten →